Horizon Therapeutics
Biopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address critical needs for people affected by rare and rheumatic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $6.0m | Series A | |
$15.0m | Series B | ||
* | $30.0m | Series C | |
| N/A | $12.0m | Debt | |
| N/A | $49.5m Valuation: $416m | IPO | |
* | N/A | $50.8m | Post IPO Equity |
* | N/A | $81.0m | Post IPO Equity |
| N/A | $150m | Post IPO Debt | |
| N/A | $300m | Post IPO Debt | |
* | N/A | $141m | POST IPO SECONDARY |
* | N/A | $862m | Post IPO Debt |
* | N/A | $300m | Post IPO Debt |
* | N/A | $345m | Post IPO Equity |
* | N/A | $600m | Post IPO Debt |
* | N/A | $963m | Post IPO Equity |
* | $28.3b Valuation: $28.3b | Acquisition | |
| Total Funding | $51.0m | ||
| USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 17 % | 21 % | 6 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 23 % | 31 % | 33 % | 33 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 47 % | 47 % | 50 % | - |
Source: Company filings or news article
Related Content
Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address critical needs for people affected by rare and rheumatic diseases. The company operates primarily in the healthcare and pharmaceutical markets, serving patients, healthcare professionals, and medical institutions globally. Horizon Therapeutics generates revenue through the sale of its proprietary medications, which are often developed through extensive research and clinical trials. The company has a robust portfolio of approved medicines and a pipeline of potential therapies aimed at treating conditions with significant unmet medical needs. Horizon Therapeutics' business model is centered around the discovery and commercialization of specialty medicines, leveraging its expertise in drug development and patient-centric approach to drive growth and improve patient outcomes. The company also collaborates with academic institutions and other organizations to advance its research and development efforts.
Keywords: biopharmaceuticals, rare diseases, rheumatic diseases, innovative medicines, patient outcomes, healthcare, pharmaceutical, clinical trials, specialty medicines, drug development.
Tech stack
